Oncolys BioPharma Inc. (4588.T)
Tokyo · JPY · Healthcare · Biotechnology
¥6,980 (+10.79%) as of
Key statistics
- Market cap
- 205.50B
- Forward P/E
- -93.07
- EPS (TTM)
- -53.18
- Dividend yield
- 0.00%
- 52-week range
- 668.00 – 7,020.00
- Beta
- 1.06
- Revenue (TTM)
- 28.55M
- Profit margin
- 0.00%
- Volume
- 1.80M
About Oncolys BioPharma Inc.
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer. The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranuclear palsy, amyotrophic lateral sclerosis, and aicardi-goutieres syndrome; OBP-702, which is in preclinical trial to treat pancreatic cancer; OBP-201, which is in preclinical trial to treat viral infections; OBP-702 for the treatment of ophthalmology which is in preclinical trial. In addition, it develops TelomeScan (OBP-401 and OBP-1101), which is in pilot study trial to treat cancer testing. The company was incorporated in 2004 and is headquartered in Minato, Japan.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Minato, Japan
- Employees
- 45
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.